Atrial Fibrillation Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Atrial Fibrillation Market Report Overview

Atrial Fibrillation market size across the 8MM was valued at $14.53 billion in 2022 and is expected to decline at a CAGR of more than 1% during 2022-2032. Atrial fibrillation (AF) is clinically defined as an irregular and often rapid heart rhythm caused by the degeneration of electrical impulses in the atria. This disorganized electrical activity of the atria results in accelerated and irregular ventricular activity, loss of atrial mechanical function, and increased risk of atrial clot formation. People may be asymptomatic or have symptoms such as chest pain, palpitations, fast heart rate, shortness of breath, nausea, dizziness, diaphoresis (severe sweating), and generalized fatigue.

Atrial Fibrillation Market Outlook, 2022-2032 ($ Billion)

Atrial Fibrillation Market Outlook, 2022-2032 ($ Billion)

To gain more information about the Atrial Fibrillation market forecast, download a free report sample

The Atrial Fibrillation market research report provides an analysis of the current and future market competition in the global Atrial Fibrillation therapeutics market. The report also offers an insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Market Size (2022) $14.53 billion
CAGR (2022 – 2032) <(1)%
Key Countries ·       The US

·       Canada

·       France

·       Germany

·       Italy

·       The UK

·       Spain

·       Japan

Leading Players ·       Boehringer Ingelheim’s Pradaxa (dabigatran)

·       Bayer’s Xarelto (rivaroxaban)

·       Bristol Myers Squibb’s (BMS) Eliquis (apixaban)

·       Daiichi Sankyo’s Savaysa (edoxaban)

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Atrial Fibrillation Market Drivers

The major factors driving the Atrial Fibrillation market are the continuous launch of pipeline products over the forecast period. A total of five pipeline products, including four anticoagulants and one cardioversion agent, will launch during the forecast period, each of which will have a higher annual cost of therapy (ACOT) when compared with the cost of generic NOACs and the commonly used pharmacological agents, respectively.

Furthermore, Factor XI (FXI)/FXIa inhibitors, including abelacimab, asundexian, and milvexian, will be welcomed by the many AF patients who are not treated with the currently available anticoagulants due to bleeding concerns.

Atrial Fibrillation Market Segmentation by Countries

Some of the key countries in the Atrial Fibrillation market in the 8MM are the US, France, Germany, Italy, the UK, Canada, Spain, and Japan. The US had the highest share of the market in 2022.

Atrial Fibrillation Market Analysis by Countries, 2022 (%)

Atrial Fibrillation Market Analysis by Countries, 2022 (%)

For more countries’ insights into the Atrial Fibrillation market, download a free report sample

Atrial Fibrillation Market - Competitive Landscape

The present AF market is highly genericized, except for those drugs indicated for stroke prevention in AF, an area now dominated by NOACs. The current AF market consists of four main NOAC brands, Boehringer Ingelheim’s Pradaxa (dabigatran), Bayer’s Xarelto (rivaroxaban), Bristol Myers Squibb’s (BMS) Eliquis (apixaban) and Daiichi Sankyo’s Savaysa (edoxaban). Bayer and Bristol Myers Squibb will continue to lead the AF market over the forecast period.

Scope

  • Overview of Atrial Fibrillation disease, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized Atrial Fibrillation therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments (mild cognitive impairment, mild Atrial Fibrillation, moderate Atrial Fibrillation, and severe Atrial Fibrillation) forecast from 2022 to 2032.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the Atrial Fibrillation therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Atrial Fibrillation treatment. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global Atrial Fibrillation therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

  • In 2022, GlobalData estimated that the global AF market reached $14.53 billion across the 8MM, and anticipates that it will decline at a negative compound annual growth rate (CAGR) of 1.3%, to be worth approximately $12.8 billion by 2032.
  • This decline in sales is due to the fact that novel oral anticoagulants (NOACs) will face generic erosion as their patents expire over the forecast period. In addition, the high cost of upcoming FXI/FXIa inhibitors compared to the NOAC generics will likely hinder patient uptake.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 8MM AF therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM AF therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Bayer
Johnson and Johnson
Bristol Myers-Squibb
Daiichi Sankyo
Pfizer
Anthos Therapeutics
Cadrenal Therapeutics
Boehringer Ingelheim
InCarda Therapeutics

Table of Contents

About GlobalData 2

1 Atrial Fibrillation: Executive Summary 9

1.1 AF market will decline at a negative CAGR of

1.3% 10

1.2 Bayer and Bristol Myers Squibb will continue to lead the AF market over the forecast period 11

1.3 While outlook in AF improves, opportunities remain to improve patient outcomes 13

1.4 Bayer’s FXIa inhibitor asundexian will be a key driver of growth 14

1.5 What do physicians think? 15

2 Introduction 17

2.1 Catalyst 17

2.2 Related reports 17

2.3 Upcoming reports 18

3 Disease Overview 19

3.1 Etiology and pathophysiology 19

3.1.1 Etiology 19

3.1.2 Pathophysiology 20

3.2 Classification 21

4 Epidemiology 22

4.1 Disease Background 22

4.2 Risk Factors and Comorbidities 25

4.3 Global and Historical Trends 27

4.4 8MM Forecast Methodology 28

4.4.1 Sources 28

4.4.2 Forecast Assumptions and Methods 37

4.4.3 Forecast assumptions and methods: total prevalent cases of AF – 8MM 37

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of AF 39

4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of AF by temporal patterns of arrhythmia 40

4.4.6 Forecast assumptions and methods: diagnosed prevalent cases of AF by CHADS2 stroke risk score 43

4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of AF by CHA2DS2 – VASc stroke risk score in men 46

4.4.8 Forecast assumptions and methods: diagnosed prevalent cases of AF by CHA2DS2 – VASc stroke risk score in women 48

4.4.9 Forecast assumptions and methods: diagnosed prevalent cases of AF with/without moderate-to-severe mitral stenosis and/or an artificial (mechanical) heart valve 50

4.4.10 Forecast assumptions and methods: diagnosed prevalent cases of AF with CKD by stage 52

4.4.11 Forecast assumptions and methods: diagnosed prevalent cases of AF with major bleeding risk by HAS‐BLED score 52

4.4.12 Forecast assumptions and methods: diagnosed prevalent cases of AF admitted to ED 54

4.5 Epidemiological Forecast for atrial fibrillation 56

4.5.1 Total prevalent cases of AF 56

4.5.2 Diagnosed prevalent cases of AF 57

4.5.3 Age-specific diagnosed prevalent cases of AF 58

4.5.4 Sex-specific diagnosed prevalent cases of AF 59

4.5.5 Diagnosed prevalent cases of AF by temporal pattern of arrhythmia 60

4.5.6 Diagnosed prevalent cases of AF by CHADS2 stroke risk score 61

4.5.7 Diagnosed prevalent cases of AF by CHA2DS2 – VASc stroke risk score in men 62

4.5.8 Diagnosed prevalent cases of AF by CHA2DS2 – VASc stroke risk score in women 63

4.5.9 Diagnosed prevalent cases of AF with or without moderate-to-severe mitral stenosis and/or an artificial (mechanical) heart valve 64

4.5.10 Diagnosed prevalent cases of AF with CKD by stage 65

4.5.11 Diagnosed prevalent cases of AF with major bleeding risk by HAS‐BLED score 66

4.5.12 Diagnosed prevalent cases of AF admitted to ED 67

4.6 Discussion 67

4.6.1 Epidemiological Forecast Insight 67

4.6.2 COVID-19 impact 69

4.6.3 Limitations of the analysis 70

4.6.4 Strengths of the analysis 71

5 Disease Management 72

5.1 Diagnosis and treatment overview 72

5.1.1 Diagnosis 72

5.1.2 Treatment 73

5.2 KOL insights on disease management 77

6 Competitive Assessment 82

6.1 Overview 82

7 Unmet Needs and Opportunity Assessment 84

7.1 Overview 84

7.2 Development of anticoagulants with reduced risk of bleeding 85

7.3 Therapies for atrial fibrillation patients with ESRD 90

7.4 Safer antiarrhythmic drugs for the maintenance of sinus rhythm 94

7.5 Effective and rapid-acting cardioversion drugs 97

8 R&D Strategies 100

8.1 Overview 100

8.1.1 Development of anticoagulants with novel MOAs to reduce bleeding risk 100

8.1.2 Targeting AF patients with ESRD 101

8.1.3 Development of non-invasive and fast-acting cardioversion agents 102

8.2 Clinical trials design 103

8.2.1 Exclusion criteria for AF clinical trials 103

9 Pipeline Assessment 106

9.1 Overview 106

9.2 Promising drugs in clinical development 107

10 Pipeline Valuation Analysis 110

10.1 Overview 110

10.2 Competitive assessment 111

10.2.1 Anticoagulant agents 111

10.2.2 Pharmacological cardioversion agents 114

11 Current and Future Players 117

11.1 Overview 117

11.2 Deal-making trends 118

12 Market Outlook 120

12.1 Global markets 120

12.1.1 Forecast 120

12.1.2 Drivers and barriers – global issues 122

12.2 US 122

12.2.1 Forecast 122

12.2.2 Key events 124

12.2.3 Drivers and barriers 124

12.3 5EU 125

12.3.1 Forecast 125

12.3.2 Key events 126

12.3.3 Drivers and barriers 126

12.4 Japan 127

12.4.1 Forecast 127

12.4.2 Key events 128

12.4.3 Drivers and barriers 128

12.5 Canada 129

12.5.1 Forecast 129

12.5.2 Key events 130

12.5.3 Drivers and barriers 130

13 Appendix 131

13.1 Bibliography 131

13.2 Abbreviations 142

13.3 Methodology 144

13.3.1 Forecasting methodology 144

13.4 Primary research – KOLs interviewed for this report 145

13.4.1 KOLs 145

13.5 Primary research – prescriber survey 146

13.6 About the Authors 147

13.6.1 Analyst 147

13.6.2 Therapy Area Director 147

13.6.3 Epidemiologist 147

13.6.4 Epidemiologist reviewers 148

13.6.5 Vice President of Disease Analysis and Intelligence 149

13.6.6 Global Head and EVP of Healthcare Operations and Strategy 149

Contact Us 150

Table

List of Tables

Table 1: Atrial fibrillation: key metrics in the 8MM 9

Table 2: Common cardiac and non-cardiac causes of AF 19

Table 3: Classification of AF 21

Table 4: Risk factors and comorbidities for AF 26

Table 5: CHADS2 index for stroke risk assessment 72

Table 6: CHA₂DS₂-VASc index for stroke risk assessment 73

Table 7: Treatment guidelines for atrial fibrillation 73

Table 8: Atrial fibrillation market – global drivers and barriers, 2022–32 122

Table 9: Key events impacting sales for atrial fibrillation in the US, 2022–32 124

Table 10: Atrial fibrillation market – drivers and barriers in the US, 2022–32 124

Table 11: Key events impacting sales for atrial fibrillation in the 5EU, 2022–32 126

Table 12: Atrial fibrillation market – drivers and barriers in the 5EU, 2022–32 126

Table 13: Key events impacting sales for atrial fibrillation in Japan, 2022–32 128

Table 14: Atrial fibrillation market – drivers and barriers in Japan, 2022–32 128

Table 15: Key events impacting sales for atrial fibrillation in Canada, 2022–32 130

Table 16: Atrial fibrillation market – drivers and barriers in Canada, 2022–32 130

Table 17: High-prescribing physicians (non-KOLs) surveyed, by country 146

Figures

List of Figures

Figure 1: Global sales forecast by country for atrial fibrillation in 2022 and 2032 11

Figure 2: Analysis of the company portfolio gap in atrial fibrillation during the forecast period 12

Figure 3: Competitive assessment of the pipeline anticoagulant drugs benchmarked against the current SOC 14

Figure 4: Competitive assessment of the pipeline drugs for pharmacological cardioversion benchmarked against the SOC 15

Figure 5: 8MM, diagnosed prevalence of AF (%), men and women, ages ≥40 years, 2022 27

Figure 6: 8MM, sources used and not used to forecast the diagnosed prevalent cases of AF 29

Figure 7: 8MM, sources used to forecast the diagnosed prevalent cases of AF by temporal pattern of arrhythmia 30

Figure 8: 8MM, sources used to forecast the diagnosed prevalent cases of AF by CHADS2 stroke risk score 31

Figure 9: 8MM, sources used to forecast the diagnosed prevalent cases of AF by CHA2DS2 – VASc score in men 32

Figure 10: 8MM, sources used to forecast the diagnosed prevalent cases of AF by CHA2DS2 – VASc score in women 33

Figure 11: 8MM, sources used to forecast the diagnosed prevalent cases of AF with/without moderate-to-severe mitral stenosis and/or an artificial (mechanical) heart valve 34

Figure 12: 8MM, sources used to forecast the diagnosed prevalent cases of AF with CKD 35

Figure 13: 8MM, sources used to forecast the diagnosed prevalent cases of AF with major bleeding risk by HAS‐BLED score 35

Figure 14: 8MM, sources used to forecast the diagnosed prevalent cases of AF admitted to the ED 36

Figure 15: 8MM, sources used to forecast the diagnosis rate of AF 36

Figure 16: 8MM, total prevalent cases of AF, N, both sexes, ages ≥40 years, 2022 56

Figure 17: 8MM, diagnosed prevalent cases of AF, N, both sexes, ages ≥40 years, 2022 57

Figure 18: 8MM, diagnosed prevalent cases of AF by age, N, both sexes, 2022 58

Figure 19: 8MM, diagnosed prevalent cases of AF by sex, N, ages ≥40 years, 2022 59

Figure 20: 8MM, diagnosed prevalent cases of AF by temporal pattern of arrhythmia, N, both sexes, ages ≥40 years, 2022 60

Figure 21: 8MM, diagnosed prevalent cases of AF by CHADS2 stroke risk score, N, both sexes, ages ≥40 years, 2022 61

Figure 22: 8MM, diagnosed prevalent cases of AF by CHA2DS2 – VASc stroke risk score in men, N, men, ages ≥40 years, 2022 62

Figure 23: 8MM, diagnosed prevalent cases of AF by CHA2DS2 – VASc stroke risk score in women, N, women, ages ≥40 years, 2022 63

Figure 24: 8MM, diagnosed prevalent cases of AF with and without moderate-to-severe mitral stenosis and/or an artificial (mechanical) heart valve, N, both sexes, ≥40 years, 2022 64

Figure 25: 8MM, diagnosed prevalent cases of AF with CKD by stage, N, both sexes, ages ≥40 years, 2022 65

Figure 26: 8MM, diagnosed prevalent cases of AF by HAS‐BLED score, N, both sexes, ages ≥40 years, 2022 66

Figure 27: 8MM, diagnosed prevalent cases of AF admitted to ED, N, both sexes, ages ≥40 years, 2022 67

Figure 28: General treatment algorithm for stroke prevention in AF 74

Figure 29: CCS guideline recommendations for choosing an anticoagulant 75

Figure 30: General treatment algorithm for long-term ventricular rate control in AF patients 76

Figure 31: Treatment algorithm for the maintenance of sinus rhythm in AF patients 77

Figure 32: Unmet needs and opportunities in AF 85

Figure 33: Overview of the development pipeline in atrial fibrillation 107

Figure 34: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for atrial fibrillation in the 8MM during the forecast period 108

Figure 35: Competitive assessment of the marketed and pipeline drugs for anticoagulation benchmarked against the SOC 114

Figure 36: Competitive assessment of the marketed and pipeline drugs for pharmacological cardioversion benchmarked against the SOC 116

Figure 37: Analysis of the company portfolio gap in AF during the forecast period 118

Figure 38: Global (8MM) sales forecast by country for atrial fibrillation in 2022 and 2032 121

Figure 39: Sales forecast by class for atrial fibrillation in the US in 2022 and 2032 123

Figure 40: Sales forecast by class for atrial fibrillation in the 5EU in 2022 and 2032 125

Figure 41: Sales forecast by class for atrial fibrillation in Japan in 2022 and 2032 127

Figure 42: Sales forecast by class for atrial fibrillation in Canada in 2022 and 2032 129

Frequently asked questions

Atrial Fibrillation Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Atrial Fibrillation Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Atrial Fibrillation Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032 in real time.

  • Access a live Atrial Fibrillation Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.